amino acid · for frequent colds
N-Acetyl Cysteine
Tops up the antioxidant your immune cells run on, and thins mucus.
Say that in clinical terms
NAC replenishes glutathione, the primary intracellular antioxidant in immune cells. It also thins mucus (mucolytic), reduces viral replication, and modulates NF-kB to optimize inflammatory response without immunosuppression.
How strong is the research?
1 paper read, 1 supporting.
Who was studied: Patients over 65 with long-term heart, lung or metabolic conditions. Healthy adults were not studied.
How much to take
daily
600–1200 mg
NAC is well-known for respiratory immune support. Take 600mg twice daily during cold and flu season.
Before you take it
- No IOM/NIH ODS Tolerable Upper Intake Level established for NAC as a dietary supplement (not an essential nutrient); adverse effects are dose-dependent and increase above 1,200 mg/day.
- Potentiates organic nitrate drugs (nitroglycerin, isosorbide dinitrate) — severe hypotension documented in cardiology settings; avoid co-administration.
- Additive anticoagulant effect with warfarin (INR monitoring required); additive antiplatelet effect with aspirin.
- Antibiotic separation required: administer NAC at least 2 hours before or 4–6 hours after tetracyclines and quinolones to prevent chelation-mediated reduction in antibiotic absorption.
- GI side effects (nausea, vomiting, diarrhea) are dose-dependent; most common at oral doses above 1,200 mg/day.
- FDA drug-exclusion position (2020): FDA classified NAC as excluded from the dietary supplement definition because it was authorized as a new drug in 1963 (Mucomyst/acetylcysteine). As of 2022, FDA exercised enforcement discretion allowing existing NAC supplements on market; no final rule published as of 2025, leaving US supplement regulatory status unsettled.
- Rare anaphylactoid reactions with IV formulations; bronchospasm with inhaled/nebulized forms; both are uncommon via oral supplementation route.
What we make of it
The benefit appeared only in a subgroup picked out after the results were in.
The detail
The trial is real and its 262 participants check out. But the drop in flu-like episodes, from around 29% to 8%, appeared only in a subgroup identified after the fact — those who already carried antibodies. That is a finding to test, not one to rely on.